ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LFVN
CING (34) CRBP (34) COYA (29) RANI (30) ⌘ Pro Terminal →

Lifevantage Corporation (Delaware) (LFVN) — RQD Stock Rating Cockpit

$5.87 -0.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.86

Lifevantage Corporation (Delaware) (LFVN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $73.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFVN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lifevantage Corporation (Delaware) (NASDAQ: LFVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $5.87 (-0.17% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, LFVN ranks #110 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFVN compare to CING and CRBP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFVN carries a Roarable C+ (67/100 RQD), trailing P/E of 7.5x, gross margin of 80.4%, and ROIC of 29.2%. By comparison, CING (Cingulate Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M) and CRBP (Corbus Pharmaceuticals Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFVN?
▼

Per LFVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000849146), Lifevantage Corporation (Delaware) generated $228.5M in revenue (+14.2% YoY), $9.8M in net income, and $10.5M in free cash flow against $61.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (80.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.86 (-0.22%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510067
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C+ · Rk C+
Cash (16)Whales (5)SEC (16)Macro (11)CEO (19)
Each axis scored 0–20
12M PRICE TARGET CONE+4.1% Base Target
$12 Bull$6 Base$5 Bear
📬 FREE LFVN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFVN)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY LFVN SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 4.6% FCF Margin ($10.5M FCF) & 80.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$5.80+2.6% Next Q
Q2 (-2Q)
62
Grade C+$5.95-1% Next Q
Q3 (-1Q)
64
Grade C+$5.89-0.3% Next Q
Current
67
Grade C+$5.87+1.6% Hist 90D α
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFVN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, LFVN faces multiple-compression risk if 7.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 77.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.12) or 200D SMA ($5.88) invalidates the momentum regime and cuts Target Base ($6.11) toward Bear Floor ($4.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LFVN Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 67%NO 33%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
43.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.98>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE25% OF RANGE
L: $4$5.87H: $12
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (80.4% gross margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on LFVN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

29.2% ROIC with 80.4% gross margin and 14.22% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 3.98 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (58)

24/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like LFVN
  • ✓Strong cash generator (80.4% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LFVN Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LFVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.92%⚡ TESTING RESISTANCE
2026-11-04O $5.88H $5.88L $5.87C $5.87VOL 17.2K
RES: $5.98SUP: $5.04SMA50: $6.12SMA200: $5.88
$12.21$10.13$8.06$5.98$3.91RES $5.98SUP $5.04$5.872026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFVN Butterfly Map → + Track LFVN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-6.7%/yr Implied 5Y Growth

vs. +14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LFVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LFVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFVN)

Health Care Rank #110 of 1015 ⚔️ CING vs LFVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFVN vs. CING, CRBP, COYA, RANI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lifevantage Corporation (Delaware) (LFVN) ranks #110 by composite RQD confidence (67/100, grade C+) and #690 by equity capitalization ($73.9M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LFVN ACTIVE
Lifevantage Corporation (Delaware)
C+ 67/100 7.5x 80.4% 29.2% -0.17% $73.9M Benchmark Subject
CING
Cingulate Inc.
E 34/100 — — -35.0% +1.00% $73.1M /cing-vs-lfvn →
CRBP
Corbus Pharmaceuticals Holdings Inc.
E 34/100 — — -35.0% -7.23% $75.7M /crbp-vs-lfvn →
COYA
Coya Therapeutics Inc.
E 29/100 — — -35.0% -10.53% $75.8M /coya-vs-lfvn →
RANI
Rani Therapeutics Holdings Inc. (Class A)
E 30/100 — — -35.0% -6.47% $76.9M /rani-vs-lfvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000849146 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lifevantage Corporation (Delaware) (LFVN) reported GAAP revenue of $228.5M (+14.2% vs. FY2024 revenue of $200.2M , and +7.1% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $11.9M, and free cash flow of $10.5M (+5.6% YoY). On the balance sheet, LFVN closed FY2025 with $61.2M in total assets against $0 in total debt (Altman Z-Score: 3.98, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $228.5M $9.8M $11.9M $10.5M $61.2M —
FY2024 (FY) 2024-06-30 $200.2M $2.9M $12.2M $10.0M $68.5M —
FY2023 (FY) 2023-06-30 $213.4M $2.5M $6.8M $6.8M — —

3. LFVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lifevantage Corporation (Delaware) (NASDAQ: LFVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $5.87 (-0.17% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, LFVN ranks #110 in composite RQD confidence.

How does LFVN compare to CING and CRBP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFVN carries a Roarable C+ (67/100 RQD), trailing P/E of 7.5x, gross margin of 80.4%, and ROIC of 29.2%. By comparison, CING (Cingulate Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M) and CRBP (Corbus Pharmaceuticals Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LFVN?

Per LFVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000849146), Lifevantage Corporation (Delaware) generated $228.5M in revenue (+14.2% YoY), $9.8M in net income, and $10.5M in free cash flow against $61.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (80.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LFVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LFVN last traded at $5.87 (-0.17% on volume of 17,237 shares), positioning the stock -4.08% below its 50-day simple moving average ($6.12) and -0.17% below its 200-day simple moving average ($5.88). Across its 52-week range of $3.90 to $11.71, LFVN sits at the 25.2% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($5.45 to $6.29).

Direct Sub-Reports: LFVN RQD Cockpit LFVN 12M Forecast LFVN Earnings & Move LFVN Dividends & DRIP LFVN Insiders & 13F LFVN Whale Options LFVN Profit Sankey LFVN News & Why
ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ SEC XBRL & RQD VERIFIED

LFVN — Lifevantage Corporation (Delaware): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lifevantage Corporation (Delaware) (LFVN) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $5.87 (-0.17% 1D, market capitalization $73.9M).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 29.2%, gross margin of 80.4%, operating margin of 5.3%, and free cash flow yield of 14.22%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (19/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.98, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lifevantage Corporation (Delaware) is listed on NASDAQ under ticker LFVN...1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Lifevantage Corporation (Delaware) (LFVN) reported $228.5M in annual revenue (up from $200.2M in FY2024, +14.2% YoY) and $9.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($213.4M revenue, $2.5M net income) through FY2025, LFVN scaled operating cash flow to $11.9M and free cash flow to $10.5M, backed by $61.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 67/100): Strong cash generator (80.4% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $3.90 – $11.71 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 7.5x trailing P/E and 5.5x EV/EBITDA against 5.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LFVN carries a macro regime beta of 1.00 and gross margin of 80.4%.

  • Key Question #1: Can LFVN sustain or expand its 5.3% operating margin and 29.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $228.5M and free cash flow of $10.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LFVN's 6.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LFVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lifevantage Corporation (Delaware) (LFVN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFVN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFVN Bull vs. Bear Conversation Board — What's Your Call at $5.87?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFVN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LFVN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $7.64 (+29.9%)
📌 Pinned Debate

Insider conviction (19/20) and a 14.22% FCF yield at a 6.3 forward P/E suggest strong cash generation is priced cheaply relative to ear

Here is why I am bullish on LFVN here at $5.88: Insider conviction (19/20) and a 14.22% FCF yield at a 6.3 forward P/E suggest strong cash generation is priced cheaply relative to earnings.. Compare LFVN's 5.3% operating margin and 29.2% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $5.59 are getting bought.

EarningsSniper 🐂 BULL

@RedlineAuditor Shorting a 5/20 institutional whale-flow stock at $5.88 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $4.47 (-24.0%)
Spot @ $5.88

Institutional flow scores only 9/20, and cash, debt, and EPS are unreported, leaving the valuation case dependent on a thinly documente

Institutional flow scores only 9/20, and cash, debt, and EPS are unreported, leaving the valuation case dependent on a thinly documented balance sheet.. Look at the math on LFVN: paying 7.5x trailing P/E for 29.2% ROIC and 5.3% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $5.17 before getting long.

LIVE TAPE